Francesco Saia,, Fesc

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2379800/publications.pdf

Version: 2024-02-01

201 papers

9,304 citations

43973 48 h-index 91 g-index

223 all docs 223 docs citations

times ranked

223

7890 citing authors

#	Article	IF	CITATIONS
1	Safety and Efficacy of Drug-Eluting and Bare Metal Stents. Circulation, 2009, 119, 3198-3206.	1.6	794
2	Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the "Real World― Circulation, 2004, 109, 190-195.	1.6	511
3	Multislice spiral computed tomography coronary angiography in patients with stable angina pectoris. Journal of the American College of Cardiology, 2004, 43, 2265-2270.	1.2	376
4	Clinical, Angiographic, and Procedural Predictors of Angiographic Restenosis After Sirolimus-Eluting Stent Implantation in Complex Patients. Circulation, 2004, 109, 1366-1370.	1.6	305
5	Safety and Efficacy of the Subclavian Approach for Transcatheter Aortic Valve Implantation With the CoreValve Revalving System. Circulation: Cardiovascular Interventions, 2010, 3, 359-366.	1.4	272
6	Coronary Restenosis After Sirolimus-Eluting Stent Implantation. Circulation, 2003, 108, 257-260.	1.6	268
7	Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet, The, 2018, 392, 835-848.	6.3	215
8	Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions. Journal of the American College of Cardiology, 2004, 43, 1954-1958.	1.2	194
9	Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. Journal of the American College of Cardiology, 2004, 43, 704-708.	1.2	191
10	Comparison Between Coronary Angioplasty and Coronary Artery Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Stenosis (the Bologna Registry). American Journal of Cardiology, 2006, 98, 54-59.	0.7	190
11	Stent fracture and restenosis in the drug-eluting stent era. Catheterization and Cardiovascular Interventions, 2004, 61, 111-116.	0.7	184
12	Incidence of High-Strain Patterns in Human Coronary Arteries. Circulation, 2004, 109, 2716-2719.	1.6	158
13	Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes. Journal of the American College of Cardiology, 2003, 41, 2093-2099.	1.2	150
14	Bicuspid Aortic Valve Stenosis. JACC: Cardiovascular Interventions, 2016, 9, 817-824.	1.1	147
15	Prevalence and Impact of Atrial Fibrillation in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic ValveÂReplacement. JACC: Cardiovascular Interventions, 2016, 9, 937-946.	1.1	145
16	Long-Term Safety and Efficacy of Drug-Eluting Stents. Circulation, 2007, 115, 3181-3188.	1.6	138
17	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management. Journal of the American College of Cardiology, 2017, 69, 2592-2603.	1.2	132
18	Restenosis rates following bifurcation stenting with sirolimus-eluting stents for de novo narrowings. American Journal of Cardiology, 2004, 94, 115-118.	0.7	124

#	Article	IF	CITATIONS
19	Sirolimus-Eluting Stent Implantation in ST-Elevation Acute Myocardial Infarction. Circulation, 2003, 108, 1927-1929.	1.6	110
20	Drug-eluting stents show delayed healing: paclitaxel more pronounced than sirolimus. European Heart Journal, 2007, 28, 974-979.	1.0	107
21	Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. European Heart Journal, 2010, 31, 35-49.	1.0	103
22	Acute kidney injury following transcatheter aortic valve implantation: incidence, predictors and clinical outcome. International Journal of Cardiology, 2013, 168, 1034-1040.	0.8	103
23	Transradial Versus Transfemoral Intervention for Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2012, 5, 23-35.	1.1	101
24	Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves. European Heart Journal, 2020, 41, 2731-2742.	1.0	97
25	Transcatheter Mitral Valve Replacement After Surgical Repair or Replacement. Circulation, 2021, 143, 104-116.	1.6	94
26	Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents. American Journal of Cardiology, 2005, 95, 167-172.	0.7	92
27	Very long sirolimus-eluting stent implantation for de novo coronary lesions. American Journal of Cardiology, 2004, 93, 826-829.	0.7	91
28	Left Main Coronary Artery Compression in Patients With Pulmonary Arterial Hypertension andÂAngina. Journal of the American College of Cardiology, 2017, 69, 2808-2817.	1.2	91
29	Mechanisms of Atherothrombosis andÂVascular Response to Primary Percutaneous Coronary Intervention inÂWomen Versus Men With AcuteÂMyocardial Infarction. JACC: Cardiovascular Interventions, 2014, 7, 958-968.	1.1	89
30	Coexistence of Degenerative Aortic Stenosis and Wild-Type Transthyretin-Related CardiacÂAmyloidosis. JACC: Cardiovascular Imaging, 2016, 9, 325-327.	2.3	89
31	Eroded Versus Ruptured Plaques at the Culprit Site of STEMI. JACC: Cardiovascular Imaging, 2015, 8, 566-575.	2.3	88
32	Clinical impact of direct referral to primary percutaneous coronary intervention following pre-hospital diagnosis of ST-elevation myocardial infarction. European Heart Journal, 2006, 27, 1550-1557.	1.0	86
33	Impact of COPD on Long-term Outcome After ST-Segment Elevation Myocardial Infarction Receiving Primary Percutaneous Coronary Intervention. Chest, 2013, 144, 750-757.	0.4	86
34	Emerging indications, in-hospital and long-term outcome of balloon aortic valvuloplasty in the transcatheter aortic valve implantation era. EuroIntervention, 2013, 8, 1388-1397.	1.4	84
35	Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry. EuroIntervention, 2017, 13, 459-466.	1.4	83
36	A Multidisciplinary Approach on theÂPerioperative Antithrombotic ManagementÂof Patients With CoronaryÂStents Undergoing Surgery. JACC: Cardiovascular Interventions, 2018, 11, 417-434.	1.1	81

#	Article	IF	CITATIONS
37	MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry. Journal of Heart and Lung Transplantation, 2020, 39, 1353-1362.	0.3	75
38	Noninvasive Assessment of Coronary Plaque Burden Using Multislice Computed Tomography. American Journal of Cardiology, 2005, 95, 1165-1169.	0.7	72
39	Optimising patient discharge management after transfemoral transcatheter aortic valve implantation: the multicentre European FAST-TAVI trial. EuroIntervention, 2019, 15, 147-154.	1.4	70
40	Effectiveness of sirolimus-eluting stent for treatment of left main coronary artery disease. American Journal of Cardiology, 2003, 92, 327-329.	0.7	68
41	Two-Year Clinical Outcomes With Drug-Eluting Stents for Diabetic Patients With De Novo Coronary Lesions. Circulation, 2008, 117, 923-930.	1.6	66
42	Timing of Oral P2Y12 Inhibitor Administration in Patients With Non-ST-Segment Elevation AcuteACoronary Syndrome. Journal of the American College of Cardiology, 2020, 76, 2450-2459.	1.2	64
43	The role of percutaneous balloon aortic valvuloplasty as a bridge for transcatheter aortic valve implantation. EuroIntervention, 2011, 7, 723-729.	1.4	63
44	Coronary Protection to Prevent Coronary Obstruction During TAVR. JACC: Cardiovascular Interventions, 2020, 13, 739-747.	1.1	58
45	Preprocedural Levels of C-Reactive Protein and Leukocyte Counts Predict 9-Month Mortality After Coronary Angioplasty for the Treatment of Unprotected Left Main Coronary Artery Stenosis. Circulation, 2005, 112, 2332-2338.	1.6	52
46	Effectiveness of sirolimus-eluting stent implantation for recurrent in-stent restenosis after brachytherapy. American Journal of Cardiology, 2003, 92, 200-203.	0.7	51
47	Treatment of very small vessels with 2.25-mm diameter sirolimus-eluting stents (from the RESEARCH) Tj ETQq $1\ 1$	0,7,84314	∤rgBT /Overl
48	Clinical outcomes for sirolimus-eluting stent implantation and vascular brachytherapy for the treatment of in-stent restenosis. Catheterization and Cardiovascular Interventions, 2004, 62, 283-288.	0.7	50
49	Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy). American Journal of Cardiology, 2005, 95, 445-451.	0.7	47
50	Short- and Long-Term Prognostic Significance of ST-Segment Elevation in Lead aVR in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2011, 108, 21-28.	0.7	47
51	In-hospital and thirty-day outcomes of the SAPIEN 3 Ultra balloon-expandable transcatheter aortic valve: the S3U registry. EuroIntervention, 2020, 15, 1240-1247.	1.4	47
52	Incidence of thrombotic stent occlusion during the first three months after sirolimus-eluting stent implantation in 500 consecutive patients. American Journal of Cardiology, 2004, 93, 1271-1275.	0.7	46
53	Predictive value of high sensitivity C-reactive protein in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention. European Heart Journal, 2007, 29, 1241-1249.	1.0	46
54	Transâ€subclavian versus transapical access for transcatheter aortic valve implantation: A multicenter study. Catheterization and Cardiovascular Interventions, 2016, 87, 332-338.	0.7	46

#	Article	IF	CITATIONS
55	Usefulness of Prehospital Triage in Patients With Cardiogenic Shock Complicating ST-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2007, 100, 787-792.	0.7	45
56	Optimisation of therapeutic strategies for ST-segment elevation acute myocardial infarction: the impact of a territorial network on reperfusion therapy and mortality. Heart, 2008, 95, 370-376.	1.2	45
57	Long-term effectiveness of early administration of glycoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous interventions: results of a registry study in an ST-elevation myocardial infarction network. European Heart Journal, 2008, 30, 33-43.	1.0	45
58	Interplay of coronary angiography and intravascular ultrasound in predicting long-term outcomes after heart transplantation. Journal of Heart and Lung Transplantation, 2015, 34, 1146-1153.	0.3	45
59	Elective sirolimus-eluting stent implantation for left main coronary artery disease: Six-month angiographic follow-up and 1-year clinical outcome. Catheterization and Cardiovascular Interventions, 2004, 62, 292-296.	0.7	44
60	Temporal course of vascular healing and neoatherosclerosis after implantation of durable- or biodegradable-polymer drug-eluting stents. European Heart Journal, 2018, 39, 2448-2456.	1.0	44
61	Long-Term Outcomes of Percutaneous Paravalvular Regurgitation Closure After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2015, 8, 681-688.	1.1	43
62	Role of residual acute stent malapposition in percutaneous coronary interventions. Catheterization and Cardiovascular Interventions, 2017, 90, 566-575.	0.7	42
63	Clinical Outcomes for Sirolimus-Eluting Stents and Polymer-Coated Paclitaxel-Eluting Stents in Daily Practice. Journal of the American College of Cardiology, 2006, 48, 1312-1318.	1.2	41
64	Long-Term Outcomes With Drug-Eluting Stents Versus Bare Metal Stents in the Treatment of Saphenous Vein Graft Disease (Results from the REgistro Regionale AngiopLastiche Emilia-Romagna) Tj ETQq0 0	0 r g.B T/0	ver ka ck 10 Tf
65	Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial. European Heart Journal, 2008, 29, 2972-2980.	1.0	41
66	Prognostic Impact of Hospital Readmissions After Primary Percutaneous Coronary Intervention. Archives of Internal Medicine, 2011, 171, 1948.	4.3	41
67	Clinical comparison of "normal-hours―vs "off-hours―percutaneous coronary interventions for ST-elevation myocardial infarction. American Heart Journal, 2007, 154, 366-372.	1.2	40
68	Risk of Adverse Cardiac and Bleeding Events Following Cardiac and Noncardiac Surgery in Patients With Coronary Stent. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 39-47.	0.9	40
69	Percutaneous mitral valve repair: The last chance for symptoms improvement in advanced refractory chronic heart failure?. International Journal of Cardiology, 2017, 228, 191-197.	0.8	40
70	Prognostic significance of mean platelet volume on admission in an unselected cohort of patients with non ST-segment elevation acute coronary syndrome. Thrombosis and Haemostasis, 2011, 106, 132-140.	1.8	38
71	Transcatheter aortic valve implantation with a selfâ \in expanding nitinol bioprosthesis. Catheterization and Cardiovascular Interventions, 2012, 79, 712-719.	0.7	37
72	Late Outcome After Stenting or Coronary Artery Bypass Surgery for the Treatment of Multivessel Disease: A Single-Center Matched-Propensity Controlled Cohort Study. Annals of Thoracic Surgery, 2005, 79, 1563-1569.	0.7	36

#	Article	IF	CITATIONS
73	Causes and timing of death during long-term follow-up after transcatheter aortic valve replacement. American Heart Journal, 2014, 168, 798-806.	1.2	36
74	Coronary artery bypass grafting vs percutaneous coronary intervention in a 'real-world' setting: a comparative effectiveness study based on propensity score-matched cohorts. European Journal of Cardio-thoracic Surgery, 2013, 44, e16-e24.	0.6	35
75	ST-Segment Elevation Myocardial Infarction Following Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2021, 77, 2187-2199.	1.2	35
76	Comparison of Effectiveness of Sirolimus-Eluting Stents Versus Bare Metal Stents for Percutaneous Coronary Intervention in Patients at High Risk for Coronary Restenosis or Clinical Adverse Events. American Journal of Cardiology, 2005, 95, 1409-1414.	0.7	33
77	Early and mid-term outcomes of 1904 patients undergoing transcatheter balloon-expandable valve implantation in Italy: results from the Italian Transcatheter Balloon-Expandable Valve Implantation Registry (ITER). European Journal of Cardio-thoracic Surgery, 2016, 50, 1139-1148.	0.6	32
78	Twenty-four months clinical outcomes of sirolimus-eluting stents for the treatment of small coronary arteries: the long-term SES-SMART clinical study. European Heart Journal, 2009, 30, 2095-2101.	1.0	31
79	Randomized comparative trial of a thin-strut bare metal cobalt-chromium stent versus a sirolimus-eluting stent for coronary revascularization. Catheterization and Cardiovascular Interventions, 2007, 69, 790-798.	0.7	30
80	Antithrombotic Management and 1-Year Outcome of Patients on Oral Anticoagulation Undergoing Coronary Stent Implantation (from the Registro Regionale Angioplastiche Emilia-Romagna Registry). American Journal of Cardiology, 2012, 109, 1411-1417.	0.7	30
81	Usefulness and Validation of the Survival posT TAVI Score for SurvivalÂAfter Transcatheter Aortic Valve Implantation forÂAortic Stenosis. American Journal of Cardiology, 2014, 114, 1867-1874.	0.7	30
82	In the era of the valve-in-valve: is transcatheter aortic valve implantation (TAVI) in sutureless valves feasible?. Annals of Cardiothoracic Surgery, 2015, 4, 214-7.	0.6	29
83	Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention—A Lescol Intervention Prevention Study (LIPS) substudy. American Heart Journal, 2005, 149, 329-335.	1.2	28
84	Long-term clinical follow-up of drug-eluting stent restenosis treatment: retrospective analysis from two high volume catheterisation laboratories. EuroIntervention, 2010, 5, 703-708.	1.4	27
85	Predicting device failure after percutaneous repair of functional mitral regurgitation in advanced heart failure: Implications for patient selection. International Journal of Cardiology, 2018, 257, 182-187.	0.8	26
86	How many patients with severe symptomatic aortic stenosis excluded for cardiac surgery are eligible for transcatheter heart valve implantation?. Journal of Cardiovascular Medicine, 2010, 11, 727-732.	0.6	25
87	Diagnostic performance of standard electrocardiogram for prediction of infarct related artery and site of coronary occlusion in unselected STEMI patients undergoing primary percutaneous coronary intervention. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 326-339.	0.4	22
88	Incidence, treatment, and outcome of acute aortic valve regurgitation complicating percutaneous balloon aortic valvuloplasty. Catheterization and Cardiovascular Interventions, 2017, 89, E145-E152.	0.7	22
89	Target Lesion Failure With Current Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2020, 13, 2868-2878.	1.1	22
90	Management and outcomes of patients with left atrial appendage thrombus prior to percutaneous closure. Heart, 2022, 108, 1098-1106.	1.2	22

#	Article	IF	CITATIONS
91	Peripheral intravascular lithotripsy for transcatheter aortic valve implantation: a multicentre observational study. EuroIntervention, 2022, 17, e1397-e1406.	1.4	21
92	Safety and efficacy of early aggressive versus cholesterol-driven lipid-lowering strategies in heart transplantation: A pilot, randomized, intravascular ultrasound study. Journal of Heart and Lung Transplantation, 2011, 30, 1305-1311.	0.3	20
93	Long-term outcome after drug eluting stenting in patients with ST-segment Elevation Myocardial Infarction. International Journal of Cardiology, 2010, 140, 154-160.	0.8	19
94	Residual aortic regurgitation is a major determinant of late mortality after transcatheter aortic valve implantation. International Journal of Cardiology, 2012, 157, 288-289.	0.8	19
95	Feasibility and safety of early discharge after transfemoral transcatheter aortic valve implantation – rationale and design of the FAST-TAVI registry. BMC Cardiovascular Disorders, 2017, 17, 259.	0.7	19
96	Does pre-existing aortic regurgitation protect from death in patients who develop paravalvular leak after TAVI?. International Journal of Cardiology, 2017, 233, 52-60.	0.8	18
97	Displacement of calcium nodules of the native valve as a possible cause of left main occlusion following transcatheter aortic valve implantation. Journal of Invasive Cardiology, 2011, 23, E106-9.	0.4	18
98	Clinical and angiographic outcomes after overdilatation of undersized sirolimus-eluting stents with largely oversized balloons: An observational study. Catheterization and Cardiovascular Interventions, 2004, 61, 455-460.	0.7	17
99	Early Adverse Impact of Transfusion After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2020, 13, e009026.	1.4	17
100	Elective sirolimus-eluting stent implantation for multivessel disease involving significant LAD stenosis: One-year clinical outcomes of 99 consecutive patients?the Rotterdam experience. Catheterization and Cardiovascular Interventions, 2004, 63, 57-60.	0.7	16
101	Safety and Long-Term Efficacy of Sirolimus Eluting Stent in ST-elevation Acute Myocardial Infarction: The REAL (Registro REgionale AngiopLastiche Emilia-Romagna) Registry. Cardiovascular Drugs and Therapy, 2006, 20, 63-68.	1.3	16
102	Paclitaxel versus sirolimus eluting stents in diabetic patients: Does stent type and/or stent diameter matter?: Longâ€term clinical outcome of 2,429â€patient multicenter registry. Catheterization and Cardiovascular Interventions, 2013, 81, 80-89.	0.7	15
103	Coronary artery disease and reasonably incomplete coronary revascularization in highâ€risk patients undergoing transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2020, 95, 19-27.	0.7	15
104	Transcatheter Aortic Valve Replacement for Residual Lesion of the Aortic Valve Following "Healed― Infective Endocarditis. JACC: Cardiovascular Interventions, 2020, 13, 1983-1996.	1.1	15
105	Balloon aortic valvuloplasty as a bridge-to-decision in high risk patients with aortic stenosis: a new paradigm for the heart team decision making. Journal of Geriatric Cardiology, 2016, 13, 475-82.	0.2	15
106	The conundrum of transient cortical blindness following coronary angiography. Journal of Cardiovascular Medicine, 2008, 9, 1063-1065.	0.6	14
107	Baseline White Blood Cell Count Is an Independent Predictor of Long-Term Cardiovascular Mortality in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome, but It Does Not Improve the Risk Classification of the GRACE Score. Cardiology, 2013, 124, 97-104.	0.6	14
108	Transcatheter aortic valve implantation (TAVI) in cardiogenic shock: TAVIâ€shock registry results. Catheterization and Cardiovascular Interventions, 2020, 96, 1128-1135.	0.7	14

#	Article	IF	Citations
109	Transcatheter aortic valve implantation in low ejection fraction/low transvalvular gradient patients. Journal of Cardiovascular Medicine, 2017, 18, 103-108.	0.6	13
110	Vascular complications after balloon aortic valvuloplasty in recent years: Incidence and comparison of two hemostatic devices. Catheterization and Cardiovascular Interventions, 2018, 91, E49-E55.	0.7	13
111	Long-term outcome of prosthesis-patient mismatch after transcatheter aortic valve replacement. International Journal of Cardiology, 2020, 318, 27-31.	0.8	13
112	Safety, efficacy and impact on frailty of mini-invasive radial balloon aortic valvuloplasty. Heart, 2021, 107, 874-880.	1.2	13
113	Impact on clinical outcomes of right ventricular response to percutaneous correction of secondary mitral regurgitation. European Journal of Heart Failure, 2021, 23, 1765-1774.	2.9	13
114	Effect of fluvastatin on long-term outcome after coronary revascularization with stent implantation. American Journal of Cardiology, 2004, 93, 92-95.	0.7	12
115	Effectiveness of sirolimus-Eluting stent implantation for coronary narrowings <50% in diameter. American Journal of Cardiology, 2004, 94, 112-114.	0.7	12
116	Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease. International Journal of Cardiology, 2005, 98, 479-486.	0.8	12
117	Clinical imaging of the vulnerable plaque in the coronary arteries: new intracoronary diagnostic methods. Journal of Cardiovascular Medicine, 2006, 7, 21-28.	0.6	12
118	Management of acute left ventricular dysfunction after primary percutaneous coronary intervention for ST elevation acute myocardial infarction. American Heart Journal, 2010, 160, S16-S21.	1.2	12
119	Incidence, prognostic value and management of vascular complications with transfemoral transcatheter aortic valve implantation. Future Cardiology, 2011, 7, 321-331.	0.5	12
120	Gender-related differences of diabetic patients undergoing percutaneous coronary intervention with drug-eluting stents: A real-life multicenter experience. International Journal of Cardiology, 2013, 168, 139-143.	0.8	12
121	Incidence and Outcome of High On-Treatment Platelet Reactivity in Patients With Non-ST Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the VIP) Tj ETQq1 1 0.784314 1792-798.	rgBT /Ove	erlock 10 Tf 5 12
122	Midâ€term outcome in patients with bicuspid aortic valve stenosis following transcatheter aortic valve	0.7	12
123	Pre-hospital ECG in patients undergoing primary percutaneous interventions within an integrated system of care: reperfusion times and long-term survival benefits. EuroIntervention, 2011, 7, 449-457.	1.4	12
124	Predictive ability of the CHADS ₂ and CHA ₂ DS ₂ -VASc scores for stroke after transcatheter aortic balloon-expandable valve implantation: an Italian Transcatheter Balloon-Expandable Valve Implantation Registry (ITER) sub-analysis. European Journal of Cardio-thoracic Surgery, 2016, 50, 867-873.	0.6	11
125	Twelve-month outcome of patients with an established indication for oral anticoagulation undergoing coronary artery stenting and stratified by the baseline risk of bleeding. Cardiovascular Revascularization Medicine, 2017, 18, 425-430.	0.3	11
126	Efficacy and safety of thrombus aspiration in ST-segment elevation myocardial infarction: an updated systematic review and meta-analysis of randomised clinical trials. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 24-38.	0.4	11

#	Article	IF	CITATIONS
127	Routine minimalist transcatheter aortic valve implantation with local anesthesia only. Journal of Cardiovascular Medicine, 2020, 21, 805-811.	0.6	11
128	Patient selection to enhance the long-term benefit of first generation drug-eluting stents for coronary revascularisation procedures. Insights from a large multicentre registry. EuroIntervention, 2009, 5, 57-66.	1.4	11
129	Lower long-term mortality within a regional system of care for ST-elevation myocardial infarction. Acute Cardiac Care, 2010, 12, 42-50.	0.2	10
130	Is balloon aortic valvuloplasty safe in patients with significant aortic valve regurgitation?. Catheterization and Cardiovascular Interventions, 2012, 79, 315-321.	0.7	10
131	Left Main Coronary Artery Extrinsic Compression in Patients With Pulmonary Arterial Hypertension. JACC: Cardiovascular Interventions, 2019, 12, 319-321.	1.1	10
132	Relation between thoracic aortic inflammation and features of plaque vulnerability in the coronary tree in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. An FDG-positron emission tomography and optical coherence tomography study. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1878-1887.	3.3	9
133	Surgery after drug-eluting stent implantation: it's not all doom and gloom!. Journal of Thoracic Disease, 2017, 9, E373-E377.	0.6	9
134	Randomized comparison of balloon aortic valvuloplasty performed with or without rapid cardiac pacing: The pacing versus no pacing (PNP) study. Journal of Interventional Cardiology, 2018, 31, 51-59.	0.5	9
135	Long-term clinical outcomes and cost-effectiveness analysis in multivessel percutaneous coronary interventions: comparison of drug-eluting stents, bare-metal stents and a mixed approach in patients at high and low risk of repeat revascularisation. EuroIntervention, 2010, 5, 953-961.	1.4	9
136	Fluvastatin Reduces Cardiac Mortality in Patients with Coronary Heart Disease. Cardiovascular Drugs and Therapy, 2004, 18, 67-75.	1.3	8
137	Left Ventricular Function After ST-Elevation Myocardial Infarction in Patients Treated With Primary Percutaneous Coronary Intervention and Abciximab or Tirofiban (from the Facilitated Angioplasty) Tj ETQq1 1 0.	78 ⊕31 4 rg	BT&Overlock
138	Paclitaxel―and sirolimusâ€eluting stents in older patients with diabetes mellitus. Catheterization and Cardiovascular Interventions, 2013, 81, 1117-1124.	0.7	8
139	Prespecified Risk Criteria Facilitate Adequate Discharge and Longâ€Term Outcomes After Transfemoral Transcatheter Aortic Valve Implantation. Journal of the American Heart Association, 2020, 9, e016990.	1.6	8
140	Modifications of medical treatment and outcome after percutaneous correction of secondary mitral regurgitation. ESC Heart Failure, 2020, 7, 1753-1763.	1.4	8
141	Setting a benchmark for resource utilization and quality of care in patients undergoing transcatheter aortic valve implantation in Europe—Rationale and design of the international <scp>BENCHMARK</scp> registry. Clinical Cardiology, 2021, 44, 1344-1353.	0.7	8
142	Long-term outcome of percutaneous coronary interventions following failed beta-brachytherapy. Journal of Invasive Cardiology, 2004, 16, 60-4.	0.4	8
143	Contemporary balloon aortic valvuloplasty: Changing indications and refined technique. Catheterization and Cardiovascular Interventions, 2021, 97, E1033-E1042.	0.7	7
144	Pattern of arterial inflammation and inflammatory markers in people living with HIV compared with uninfected people. Journal of Nuclear Cardiology, 2022, 29, 1566-1575.	1.4	7

#	Article	IF	CITATIONS
145	Sex based analysis of the impact of red blood cell transfusion and vascular or bleeding complications related to TAVI – The TRITAVI-Women Study. International Journal of Cardiology, 2021, 333, 69-76.	0.8	7
146	Transcatheter Aortic Valve Replacement for Pure Aortic Regurgitation in a LargeÂand Noncalcified Annulus. JACC: Cardiovascular Interventions, 2021, 14, e271-e273.	1.1	7
147	Effectiveness of the sirolimus-eluting stent in the treatment of patients with a prior history of coronary artery bypass graft surgery. Coronary Artery Disease, 2004, 15, 171-175.	0.3	6
148	Review: The safety of drug-eluting stents. Therapeutic Advances in Cardiovascular Disease, 2008, 2, 43-52.	1.0	6
149	Comparison of Balloon-Expandable Versus Self-Expandable Valves for Transcatheter Aortic Valve Implantation in Patients With Low-Gradient Severe Aortic Stenosis and Preserved Left Ventricular Ejection Fraction. American Journal of Cardiology, 2015, 115, 810-815.	0.7	6
150	Prognostic significance of shockable and non-shockable cardiac arrest in ST-segment elevation myocardial infarction patients undergoing primary angioplasty. Resuscitation, 2018, 123, 8-14.	1.3	6
151	Long-term percentage of ventricular pacing in patients requiring pacemaker implantation after transcatheter aortic valve replacement: A multicenter 10-year experience. Heart Rhythm, 2020, 17, 1897-1903.	0.3	6
152	Risk of Stroke in Patients With High On-Clopidogrel Platelet Reactivity to Adenosine Diphosphate After Percutaneous Coronary Intervention. American Journal of Cardiology, 2014, 113, 1807-1814.	0.7	5
153	Newâ€generation drugâ€eluting stents reduce stent thrombosis and myocardial infarction: A propensityâ€scoreâ€adjusted analysis from the multicenter REAL registry (REgistro Regionale) Tj ETQq1 1 0.7845	314.rgBT /	Oyerlock 10
154	Impact of Culprit Plaque and Atherothrombotic Components on Incomplete Stent Apposition in Patients With ST-Elevation Myocardial Infarction Treated With Everolimus-Eluting Stents – An OCTAVIA Substudy –. Circulation Journal, 2016, 80, 895-905.	0.7	5
155	Relationship between Serum Inflammatory Biomarkers and Thrombus Characteristics in Patients with ST Segment Elevation Myocardial Infarction. Cardiology, 2017, 137, 27-35.	0.6	5
156	MitraClip Treatment of Secondary Mitral Regurgitation in Heart Failure with Reduced Ejection Fraction: Lessons and Implications from Trials and Registries. Structural Heart, 2020, 4, 247-253.	0.2	5
157	Combined Procedure of Percutaneous Mitral Valve Repair and Left Atrial Appendage Occlusion. JACC: Cardiovascular Interventions, 2021, 14, 590-592.	1.1	5
158	Transcatheter aortic valve implantation for severe autograft regurgitation after Ross operation. EuroIntervention, 2014, 10, 141-145.	1.4	5
159	Repeated Aortic Balloon Valvuloplasty in Elderly Patients With Aortic Stenosis Who Are Not Candidates for Definitive Treatment. Journal of Invasive Cardiology, 2015, 27, E277-84.	0.4	5
160	Impact of a territorial ST-segment elevation myocardial infarction network on prognosis of patients with out-of-hospital cardiac arrest. Acute Cardiac Care, 2011, 13, 143-147.	0.2	4
161	Utility of stress perfusion-cardiac magnetic resonance in follow-up of patients undergoing percutaneous coronary interventions of the left main coronary artery. International Journal of Cardiovascular Imaging, 2017, 33, 1589-1597.	0.7	4
162	Optical coherence tomography assessment of macrophages accumulation in non-ST-segment elevation acute coronary syndromes. Journal of Cardiovascular Medicine, 2020, 21, 860-865.	0.6	4

#	Article	IF	CITATIONS
163	Impact of coronary bypass or stenting on mortality and myocardial infarction in stable coronary artery disease. International Journal of Cardiology, 2020, 309, 63-69.	0.8	4
164	Quantification of scientific output in cardiovascular medicine: a perspective based on global data. EuroIntervention, 2013, 9, 975-978.	1.4	4
165	Surgical Risk Scores Applied to Transcatheter Aortic Valve Implantation: Friends or Foes? Short-Term and Long-Term Outcomes From a Single-Center Registry. Journal of Invasive Cardiology, 2019, 31, E282-E288.	0.4	4
166	Incidence, treatment and outcome of acute coronary syndromes: A community-based study in the era of myocardial infarction networks. International Journal of Cardiology, 2012, 157, 419-422.	0.8	3
167	Predictors of complicated athero-thrombotic lesions in non-ST segment acute coronary syndrome. Journal of Cardiovascular Medicine, 2013, 14, 430-437.	0.6	3
168	Cognitive functions: evaluation and changes after transcatheter aortic valve implantation in elderly patients. Future Cardiology, 2017, 13, 229-237.	0.5	3
169	Fate of Nonculprit Plaques in Patients With STEMI Undergoing Primary PCI Followed by Statin Therapy. JACC: Cardiovascular Imaging, 2017, 10, 827-829.	2.3	3
170	Comparative assessment of "plaque/media―change on three modalities of IVUS immediately after implantation of either everolimus-eluting bioresorbable vascular scaffold or everolimus-eluting metallic stent in Absorb II study. International Journal of Cardiovascular Imaging, 2017, 33, 441-449.	0.7	3
171	Predicting and improving outcomes of transcatheter aortic valve replacement in older adults and the elderly. Expert Review of Cardiovascular Therapy, 2020, 18, 663-680.	0.6	3
172	Balloon pulmonary angioplasty after pulmonary thromboendarterectomy. Annals of Cardiothoracic Surgery, 2022, 11, 192-194.	0.6	3
173	Therapeutic alternatives in chronic thromboembolic pulmonary hypertension: from pulmonary endarterectomy to balloon pulmonary angioplasty to medical therapy. State of the art from a multidisciplinary team. Annals of Cardiothoracic Surgery, 2022, 11, 120-127.	0.6	3
174	Coronary stenting for unstable angina. Coronary Artery Disease, 1999, 10, 81-88.	0.3	2
175	Prodromal angina and risk of 2-year cardiac mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention. Medicine (United States), 2018, 97, e12332.	0.4	2
176	Balloon Aortic Valvuloplasty Today. JACC: Cardiovascular Interventions, 2020, 13, 592-593.	1.1	2
177	Innovative transcatheter procedures for the treatment of heart failure. Cardiovascular Diagnosis and Therapy, 2021, 11, 292-300.	0.7	2
178	Risk of Stroke in Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention versus Optimal Medical Therapy: Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2016, 11, e0158769.	1.1	2
179	Percutaneous treatment of paravalvular leaks after transcatheter aortic valve implantation with the CoreValve self-expanding bioprosthesis. EuroIntervention, 2013, 9, 292-292.	1.4	2
180	Drug-eluting stents. The third revolution in percutaneous coronary intervention. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2005, 6, 289-303.	0.1	2

#	Article	IF	CITATIONS
181	Management and outcome of major bleeding in patients on triple therapy after coronary stenting. Clues from the WARfarin and coronary STENTing (WAR-STENT) registry. Journal of Cardiovascular Medicine, 2015, 16, 520-521.	0.6	1
182	Reply. Journal of the American College of Cardiology, 2017, 70, 2460-2461.	1.2	1
183	Bring the old boysâ€"and girlsâ€"Back home. Catheterization and Cardiovascular Interventions, 2019, 94, 456-457.	0.7	1
184	Shifting the attention from devices to treatment: the lesson from IABP-SHOCK II and other trials in cardiogenic shock. Journal of Thoracic Disease, 2019, 11, E206-E209.	0.6	1
185	Downstream or upstream administration of P2Y12 receptor blockers in non-ST elevated acute coronary syndromes: study protocol for a randomized controlled trial. Trials, 2020, 21, 966.	0.7	1
186	Rapid pacing using device programmers: A complex procedural simplification?. Catheterization and Cardiovascular Interventions, 2020, 95, 1049-1050.	0.7	1
187	Long-term echocardiographic findings after TAVR: 5-year follow-up in 400 consecutive patients. Internal and Emergency Medicine, 2021, 16, 1873-1882.	1.0	1
188	Evolution of STEMI network in Italy. Minerva Cardiology and Angiology, 2018, 66, 392-399.	0.4	1
189	Emergency balloon aortic valvuloplasty in patients with critical aortic stenosis presenting with cardiogenic shock. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2005, 6, 420-3.	0.1	1
190	Cardiac FDG PET/CT is useful to assess the culprit lesion in nonST-segment elevation myocardial infarction (NSTEMI). European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 642-643.	3.3	0
191	Invited Commentary. Annals of Thoracic Surgery, 2013, 96, 1328.	0.7	0
192	Reply. JACC: Cardiovascular Interventions, 2015, 8, 869-870.	1.1	0
193	Transcatheter Mitral Valve-in-Valve Dislocation: AÂRescue Strategy. Annals of Thoracic Surgery, 2018, 106, e137-e139.	0.7	O
194	Multi-Imaging Investigation to Evaluate the Relationship between Serum Cystatin C and Features of Atherosclerosis in Non-ST-Segment Elevation Acute Coronary Syndrome. Applied Sciences (Switzerland), 2019, 9, 657.	1.3	0
195	Suprasternal access for transcatheter aortic valve implantation: All ways lead to Rome. Catheterization and Cardiovascular Interventions, 2020, 95, 1184-1185.	0.7	0
196	Impact of Elective, Uncomplicated Target Lesion Revascularization on Cardiac Mortality After Elective Percutaneous Coronary Intervention of Unprotected Left Main Coronary Artery Disease. American Journal of Cardiology, 2020, 128, 94-100.	0.7	0
197	Reply. JACC: Cardiovascular Interventions, 2020, 13, 1382-1383.	1.1	0
198	Women and transcatheter aortic valve implantation: Also a mismatch could be tomorrow's best match. Catheterization and Cardiovascular Interventions, 2021, 97, 527-528.	0.7	0

#	Article	IF	CITATIONS
199	How to reduce uncommon but severe transcatheter aortic valve implantation complications: stroke, thrombosis, endocarditis, cognitive decline?. European Heart Journal Supplements, 2021, 23, E142-E146.	0.0	O
200	How should I treat an unexpected deadlock at the time of transcatheter aortic valve prosthesis implantation?. EuroIntervention, 2017, 13, e256-e258.	1.4	0
201	Transcatheter edgeâ€toâ€edge mitral valve repair: Should we stay tied to COAPT tiers?. Catheterization and Cardiovascular Interventions, 2021, 98, 1413-1414.	0.7	0